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Abstract
Introduction: We investigated whether tumour markers carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cancer antigen 125 (CA-
125), and cytokeratin 19 fragment (CYFRA 21-1) in pleural effusions and serum can be used to distinguish pleural effusion aetiology. 
Materials and methods: During the first thoracentesis, we measured pleural fluid and serum tumour marker concentrations and calculated the 
pleural fluid/serum ratio for patients diagnosed with pleural effusion, using electrochemiluminescence immunoassays. Receiver operating characte-
ristic (ROC) analysis was carried out and the Hanley and McNeil method was used to test the significance of the difference between the areas under 
ROC curves (AUCs). In order to detect which tumour marker best discriminates between malignant and non-malignant pleural effusions and to esta-
blish the predictive value of those markers, discriminant function analysis (DFA) and logistic regression analysis were utilized.
Results: Serum tumour markers CYFRA 21-1 and NSE as well as pleural NSE were good predictors of pleural effusion malignancy and their combined 
model was found statistically significant (Chi-square = 28.415, P < 0.001). Respective ROC analysis showed significant discrimination value of the 
combination of these three markers (AUC = 0.79).
Conclusions: Serum markers showed superiority to pleural fluid markers in determining pleural fluid aetiology. Serum CYFRA 21-1 and NSE concen-
trations as well as pleural fluid NSE values had the highest clinical value in differentiating between malignant and non-malignant pleural effusions. 
The combination of these three markers produced a significant model to resolve pleural effusion aetiology.
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Introduction
Pleural effusion is the accumulation of liquid in the 
pleural cavity and, in most cases, is considered a 
result of a systemic or intrathoracic process. This 
pathological entity is a frequent problem in pul-
monology and, though its incidence varies with 
clinical background, 90% of all pleural effusions 
are attributed to congestive heart failure, malig-
nant processes, and pneumonia (1).
The main issues regarding pleural effusions are the 
differentiation of exudates and transudates and 
the accurate determination of effusion aetiology 
(i.e. whether the pleural effusion is malignant or 
non-malignant). The differentiation of exudates 
and transudates requires the evaluation of various 
biochemical parameters and their comparison in 
pleural fluid and serum. When differentiating tran-
sudates from exudates using classical Light’s crite-
ria, it is helpful to recognize the pathogenic mech-
anism resulting in the pleural effusion. Recogniz-
ing the correct pathogenic mechanism is also use-
ful for the purpose of differential diagnosis (2). 
Biochem Med (Zagreb) 2018;28(1):010706  https://doi.org/10.11613/BM.2018.010706 
2
Volarić D. et al. Tumour markers in pleural effusions
When referring to the effusion aetiology, non-ma-
lignant pleural effusions are twice as common as 
malignant effusions and have diverse causes and 
manifestations, making them a diagnostic chal-
lenge (3). Evaluating an effusion’s potential malig-
nancy is crucial for patient management and prog-
nosis. Cytological examination is frequently used 
as a simple and non-invasive procedure to evalu-
ate the malignancy of a pleural effusion, but more 
procedures are needed to confirm malignant pleu-
ral effusion aetiology in the case of a negative cy-
tological examination. The methods used for this 
confirmation, such as thoracoscopy, are often haz-
ardous and difficult to perform. In an attempt to 
help in the differentiation of pleural effusion aeti-
ologies, many studies have tried to examine tu-
mour markers as a possible alternative to invasive 
procedures (4). Various studies have investigated 
the value of tumour markers in evaluating cancer 
patients as screening, diagnostic, prognostic, or 
monitoring tools (5-8). 
The objective of the present study was to deter-
mine whether tumour-related biomarkers in pleu-
ral effusions and serum can be used to distinguish 
malignant and non-malignant pleural effusions. 
Our hypothesis was that tumour markers are a 
worthy substitute of the presence of malignant 
cells in pleural fluid as malignancy markers. We in-
vestigated four tumour markers in Croatian pa-
tients: carcinoembryonic antigen (CEA), neuron-
specific enolase (NSE), cancer antigen 125 (CA-125), 
and cytokeratin 19 fragment (CYFRA 21-1).
Materials and methods
Subjects
During the first thoracentesis, a total of 110 pleural 
fluid and serum samples were collected prospec-
tively from 110 consecutive patients diagnosed 
with pleural effusion and admitted to the Depart-
ment of Pulmonology at Clinical Hospital Centre in 
Rijeka, Croatia, between November 2013 and No-
vember 2014. Measurements were made at the 
time of admission to the Clinical Hospital Centre. 
After excluding 10 patients with unknown pleural 
effusion origin, 100 patients formed the study 
group. The 10 excluded patients were not fol-
lowed up because 7 patients refused additional 
treatment and/or diagnostics and 3 suffered a fatal 
outcome (Figure 1). 
Informed consent was obtained from all patients 
included in the study. All procedures were per-
formed in accordance to the ethical standards of 
Figure 1. Flowchart showing the patient recruitment process
Participants diagnosed with pleural eusion
N = 110
Participants diagnosed
with pleural eusion of dened aetiology
N = 100
Participants excluded
due to unknown pleural eusion aetiology 
N = 10
Participants who refused
additional treatment
and/or diagnostics
N = 7
Participants with diagnosed
malignant pleural eusion
(malignant group)
N = 55
Participants with diagnosed
non-malignant pleural eusion
(non-malignant group)
N = 45
Participants who suered
a fatal outcome
N = 3
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the institutional and national research committee, 
and the 1964 Helsinki declaration and its later 
amendments or comparable ethical standards. 
The study protocol was authorized by the ethics 
committee of the relevant Clinical Hospital Centre.
Methods
Pleural effusion was diagnosed after thorough an-
amnesis, physical examination (lung percussion 
and auscultation), and chest x-ray. Pleural effusion 
was confirmed by thoracentesis.
Blood was sampled by venipuncture of antecubi-
tal veins. Pleural fluid was collected by a needle in-
serted between the seventh and ninth rib spaces, 
between the posterior axillary line and midline 
(thoracentesis). Both blood and pleural fluid were 
collected in 7 mL biochemical tubes without anti-
coagulants (BD vacutainer systems, Plymouth, UK). 
Blood and pleural specimens were centrifuged at 
a relative centrifugal force (RCF) of 1917xg for 10 
minutes and the supernatant was analysed imme-
diately. Blood specimens were tested at least 30 
minutes after sampling, whereas pleural fluid sam-
ples were analysed immediately without previous 
storage. Tumour marker concentrations were de-
termined by electrochemiluminescence immuno-
assays on the Cobas® e601 analyser (Roche-Diag-
nostics, Mannheim, Germany). The readers of the 
tests and reference standards were professionals, 
blind to the results of the other test.
Transudative and exudative pleural effusions were 
differentiated by Light’s criteria: effusion/serum 
protein ratio > 0.5, effusion/serum LD ratio > 0.6, 
effusion LD activity greater than two-thirds the 
upper limit of the laboratory’s reference range for 
serum LD (9,10). The finding of one of these criteria 
suggested exudate.
If malignant cells were detected in a smear of the 
pleural effusion sediment using the May-Grün-
wald-Giemsa staining method under a light micro-
scope, the effusion was recognized as malignant. 
Pleural effusions from patients with previously di-
agnosed malignant illness were also considered 
malignant if other diseases were excluded as the 
cause. This method of diagnosing malignant pleu-
ral effusions was the usual clinical procedure used 
for defining malignant pleural effusions and re-
garded as the reference standard (11). Patients 
who had bacteria in the pleural effusion, severe fe-
brile ailment, or lung infiltrates on chest x-ray with 
no other reason for pleural effusion were diag-
nosed with parapneumonic effusion or pyothorax 
(12). Patients who presented with physical symp-
toms of myocardial congestion and typical x-ray 
signs, also considering electrocardiography and 
echocardiography, were diagnosed with conges-
tive heart failure. Other causes of pleural effusion, 
such as liver cirrhosis, chronic renal failure, and as-
bestosis, were also differentiated and classified as 
other known causes. 
Statistical analysis
Statistical analyses were performed using Med-
Calc software version 12.7.0.0 (Mariakerke, Bel-
gium) and Statistica version 13 (Dell Inc., Tulsa, 
USA). Variables were tested for normality using a 
Kolmogorov-Smirnov test. Continuous variables 
with normal distribution were expressed as mean 
± standard deviation (SD) and those with non-nor-
mal distribution as median and interquartile range 
(IQR). To test the difference in tumour marker con-
centrations between malignant and benign pleu-
ral effusions, we used the non-parametric Mann-
Whitney U-test because the variables were not 
normally distributed. To determine the clinical 
usefulness of tumour markers in the studied group 
and assess the performance of tumour markers in 
distinguishing malignant and non-malignant pleu-
ral effusions, the marker values were reviewed by 
a receiver operating characteristic (ROC) analysis. 
The area under the ROC curve (AUC) serves as an 
overall measure of a biomarker/diagnostic test’s 
accuracy (13,14).
The diagnostic accuracy of each tumour marker 
and its pleural fluid/serum ratio was determined 
by sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), positive 
likelihood ratio (LR+), negative likelihood ratio (LR-) 
and the AUC. We used Hanley and McNeil’s meth-
od for pairwise comparison of ROC curves in order 
to test the difference between the AUCs. P < 0.05 
was considered significant. 
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In order to detect the tumour markers which best 
discriminate between malignant and non-malig-
nant pleural effusions, discriminant function anal-
ysis (DFA) was employed. Logistic regression anal-
ysis was performed in order to establish the pre-
dictive value of those markers.
We calculated the required sample size using Med-
Calc software assuming that the desired statistical 
power of the test is 90% with a confidence level of 
95% and the ratio of sample sizes in the negative 
and positive groups is 1. We wanted to show that 
the expected AUC of 0.7 for a particular test is sig-
nificant from the null hypothesis value of 0.5. The 
required sample size was calculated to be 82. The 
present study had a slightly larger sample size to 
ensure that we would have enough results if some 
of the patients were excluded later.
Results
The study group consisted of 73% males (73 male 
and 27 females). The median age of the study 
group was 71 years (range 22 - 92 years). In 88 pa-
tients (88%), we found a unilateral pleural effusion, 
whereas 12 (12%) patients were diagnosed with a 
bilateral effusion. The time interval between defin-
ing the pleural effusion as malignant or non-ma-
lignant and the determination of tumour marker 
concentrations was approximately 7 days. No ad-
verse events occurred as a result of venipuncture 
or thoracentesis.
According to Light’s criteria, pleural exudates 
made up 71% (N = 71) of the study group; the oth-
er 29% (N = 29) were pleural transudates (Table 1). 
The main cause of pleural exudates was malignant 
disease while the main cause of pleural transu-
dates was heart failure (Table 1).
Primary tumour sites in malignant pleural effu-
sions were distributed as follows: lung (N = 17), 
pleura (N = 15), ovary (N = 4), colon (N = 4), stom-
ach (N = 3), breast (N = 2), prostate (N = 2), malig-
nant disease of unknown origin (N = 2), skin (N = 
1), soft tissues (N = 1), pancreas (N = 1), oesopha-
gus (N = 1), hypopharynx (N = 1), and lymph nodes 
(N = 1). The non-malignant or benign pleural effu-
sion group (N = 45) consisted of all patients with 
pleural transudates or non-malignant pleural exu-
dates, who were then compared to the patients di-
agnosed with malignant pleural effusions (N = 55). 
The median age of the patients with malignant 
pleural effusions was 70 (48 – 90) years; whereas 
the median age of the patients with non-malig-
nant pleural effusions was 73 (22 – 92) years.
The gender distribution was 39 males and 16 fe-
males in the malignant group and 34 males and 11 
women in the non-malignant pleural effusion 
group. The concentrations of tumour markers CEA, 
NSE, CA-125, and CYFRA 21-1 in pleural fluid (P), se-
rum (S) and their pleural fluid/serum ratios (R) in 
the malignant and non-malignant patient group 
are presented in Table 2. Pleural fluid CEA, NSE and 
CYFRA 21-1, as well as serum NSE and CYFRA 21-1 
concentrations were significantly higher in malig-
nant effusions than in benign effusions. The pleu-
ral fluid/serum ratios for CEA and NSE were signifi-
cantly higher in malignant than in benign effu-
sions. CA-125 was the only marker to show no sig-
nificant difference in pleural fluid or serum con-
centrations or their ratio.
The ROC analyses of the mentioned tumour mark-
ers (determined in pleural fluid, serum, and as 
pleural fluid/serum ratio) are shown in Table 3 with 
Pleural exudates N / total
malignant 55 / 71
parapneumonic 7 / 71
asbestosis 4 / 71
rib fracture 1 / 71
heart failure 1 / 71
liver cirrhosis 1 / 71
glomerulonephritis 1 / 71
hemopneumothorax 1 / 71
Pleural transudates
heart failure 22 / 29
liver cirrhosis 3 / 29
chronic renal failure 2 / 29
asbestosis 1 / 29
rib fracture 1 / 29
Table 1. Differentiation of pleural effusions according to Light’s 
criteria with pleural fluid aetiology
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Tumour marker Malignant (N = 55)
Non-malignant 
(N = 45) P
(P) CA-125, mU/mL 814.3 (215.8 - 1107.0) 732.7 (278.1 - 984.6) 0.368
(S) CA-125, mU/mL 175.3 (42.5 - 299.5) 166.8 (62.2 - 303.5) 0.967
(R) CA-125 3.9 (1.9 - 8.2) 3.8 (1.7 - 7.5) 0.819
(P) CEA, µg/mL 3.0 (1.0 - 92.6) 0.9 (0.3 - 1.6) < 0.001
(S) CEA, µg/mL 3.0 (1.6 - 6.7) 2.4 (1.3 - 3.6) 0.070
(R) CEA 0.9 (0.5 - 7.6) 0.4 (0.2 - 0.7) < 0.001
(P) NSE, ng/mL 10.8 (5.3 - 31.0) 4.4 (2.2 - 11.2) < 0.001
(S) NSE, ng/mL 19.4 (14.5 - 27.0) 12.7 (10.7 - 17.4) < 0.001
(R) NSE 0.6 (0.3 - 1.3) 0.3 (0.2 - 0.1) 0.047
(P) CYFRA 21-1, ng/mL 57.5 (22.4 - 161.9) 13.0 (6.3 - 48.6) < 0.001
(S) CYFRA 21-1, ng/mL 7.9 (3.6 - 14.9) 2.2 (1.4 - 4.4) < 0.001
(R) CYFRA 21-1 7.7 (2.8 - 27.4) 4.0 (2.6 - 24.0) 0.484
Data are presented as median and interquartile range (IQR). P – pleural fluid concentration. S – serum concentration. R - pleural 
fluid/serum ratio. P < 0.05 was considered statistically significant.
Table 2. Tumour marker concentrations and pleural fluid/serum ratios in the malignant and non-malignant patient group
Tumour 
marker Cut-off Sensitivity Specificity PPV NPV AUC, P LR+ LR-
(P) CA-125, 
mU/mL > 844.2
49.1 
(35.4 - 62.9)
66.7 
(51.0 - 80.0)
64.3 
(48.0 - 78.4)
51.7 
(38.1 - 65.2)
0.55 (0.45 – 0.65), 
0.363 1.47 0.76
(S) CA-125, 
mU/mL ≤ 50.5
30.9 
(19.1 - 44.8)
82.2 
(67.9 - 92.0)
68.0 
(46.5 - 85.1)
49.3 
(37.6 - 61.1)
0.50 (0.40 – 0.60), 
0.964 1.74 0.84
(R) CA-125 > 0.92 87.3 (75.5 - 94.7)
20.0 
(9.6 - 34.6)
57.1 
(45.9 - 67.9)
56.2 
(29.9 - 80.2)
0.51 (0.41 – 0.62), 
0.818 1.09 0.64
(P) CEA, 
µg/mL > 2.2
56.4 
(42.3 - 69.7)
88.9 
(75.9 - 96.3)
86.1 
(70.5 - 95.3)
62.5 
(49.5 - 74.3)
0.75 (0.65 – 0.83), 
< 0.001 5.07 0.49
(S) CEA, 
µg/mL > 3.9
38.2 
(25.4 - 52.3)
84.4 
(70.5 - 93.5)
75.0 
(55.1 - 89.3)
52.8 
(40.7 - 64.7)
0.61 (0.50 – 0.70), 
0.061 2.45 0.73
(R) CEA > 0.56 69.1 (55.2 - 80.9)
82.2 
(67.9 - 92.0)
82.6 
(68.6 - 92.2)
68.5 
(54.3 - 80.6)
0.80 (0.71 – 0.874), 
< 0.001 3.89 0.38
(P) NSE, 
ng/mL > 4.9
81.8 
(69.1 - 90.9)
57.8 
(42.2 - 72.3)
70.3 
(57.6 - 81.1)
72.2 
(54.5 - 86.0)
0.70 (0.60 - 0.79), 
< 0.001 1.94 0.31
(S) NSE, 
ng/mL > 13.3
81.8 
(69.1 - 90.9)
57.8 
(42.2 - 72.3)
70.3 
(57.6 - 81.1)
72.2 
(54.5 - 86.0)
0.73 (0.63 – 0.82), 
< 0.001 1.94 0.31
(R) NSE > 0.32 72.7 (59.0 - 83.9)
53.3 
(37.9 - 68.3)
65.6 
(52.3 - 77.3)
61.5 
(44.6 - 76.6)
0.62 (0.52 – 0.71),  
0.043 1.56 0.51
(P) CYFRA 
21-1, ng/mL > 14.1
83.6 
(71.2 - 92.2)
55.6 
(40.0 - 70.4)
69.7 
(57.1 - 80.4)
73.5 
(55.6 - 87.1)
0.72 (0.62 – 0.80), 
< 0.001 1.88 0.29
(S) CYFRA 
21-1, ng/mL > 3.5
76.4 
(63.0 - 86.8)
71.1 
(55.7 - 83.6)
76.4 
(63.0 - 86.8)
71.1 
(55.7 - 83.6)
0.79 (0.69 – 0.86), 
< 0.001 2.64 0.33
(R) CYFRA 
21-1 > 7.62
50.9 
(37.1 - 64.6)
66.7 
(51.0 - 80.0)
65.1 
(49.1 - 79.0)
52.6 
(39.0 - 66.0)
0.54 (0.44 – 0.64) 
0.489 1.53 0.74
P – pleural fluid concentration. S – serum concentration. R - pleural fluid/serum ratio. Sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV) and area under the curve (AUC) are presented as percentage with corresponding 95% 
confidence intervals. (LR+) - positive likelihood ratio. (LR-) - negative likelihood ratio. P < 0.05 was considered statistically significant.
Table 3. Diagnostic accuracy characteristics for the investigated tumour markers and pleural fluid/serum ratios
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their cut-off points and corresponding diagnostic 
characteristics. We selected the positivity cut-off 
points after performing the test, choosing the 
ones that maximized tumour marker performance. 
The best cut-off values were based on the ROC 
analysis performed using MedCalc software. The 
marker values with the highest AUCs were the (R) 
CEA (AUC = 0.80), (S) CYFRA 21-1 (AUC = 0.79), (P) 
CEA (AUC = 0.75), (S) NSE (AUC = 0.73), (P) CYFRA 
21-1 (AUC = 0.72) and (P) NSE (AUC = 0.70). The 
ROC curves for all measured entities are presented 
in Figure 2.
After pairwise comparison of all 12 ROC curves, 
significant differences were shown between AUCs 
of (S) CYFRA 21-1, (R) CEA, (P) CEA, (S) NSE, (P) NSE, 
(P) CYFRA 21-1, while no difference was found 
comparing AUCs of (P) CA-125, (R) CA-125, (S) CA-
125 and (R) CYFRA 21-1 (data not shown). These re-
sults show that there are significant differences 
between diagnostic values of these tumour mark-
ers. However, there was no statistically significant 
difference between AUCs for tumour markers (S) 
CYFRA 21-1, (R) CEA, (P) CEA, (S) NSE, (P) NSE, (P) 
CYFRA 21-1 (data not shown) and therefore it can-
Figure 2. Receiver operating characteristics (ROC) curves for all parameters investigated in pleural fluid, serum and their ratios. P – 
pleural fluid concentration. S – serum concentration. R - pleural fluid/serum ratio.
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not be concluded that any of them had greater di-
agnostic accuracy in distinguishing malignant 
from non-malignant pleural effusions. In order to 
better explain these results, DFA was performed.
Sets of four tumour markers concentrations meas-
ured in pleural fluid and serum, as well as their ra-
tios were analysed with respect to their discrimi-
natory ability, and the results presented in Table 4. 
Serum tumour markers have significant discrimi-
nant ability with respect to malignancy of pleural 
effusions, while pleural markers did not produce a 
Tumour marker b SE (b) Wald P
Tumour marker combination
Chi-square P AUC 95% CI
(S) CYFRA 21-1 0.096 0.041 5.507 0.019
28.415 < 0.001 0.79 0.69 - 0.86(S) NSE 0.122 0.037 10.976 < 0.001
(P) NSE 0.025 0.012 4.544 0.033
P – pleural fluid concentration. S – serum concentration. R - pleural fluid/serum ratio. 95% CI – 95% confidence intervals. P < 0.05 
was considered statistically significant. b -  logistic regression coefficient and its standard error SE (b). The statistical significance of 
individual regression coefficients is tested using the Wald Chi-square statistic. If P < 0.05 then the variable contributes significantly 
to the outcome prediction. AUC  – area under the ROC curve.
Tumour 
marker
Wilks’ 
lambda F P
F 
(model)
P 
(model)
(P) CA-125
(P) CEA 
(P) NSE 
(P) CYFRA 21-1
0.918
0.911
0.965
0.913
1.136
0.441
6.098
0.647
0.289
0.508
0.015
0.423
2.431 0.053
(S) CA-125
(S) CEA
(S) NSE 
(S) CYFRA 21-1
0.854
0.853
0.903
0.907
0.254
0.101
5.693
6.136
0.616
0.751
0.019
0.015
4.139 0.004
(R) CA-125
(R) CEA
(R) NSE 
(R) CYFRA 21-1
0.952
0.984
0.970
0.963
0.434
3.660
2.231
1.593
0.512
0.059
0.139
0.210
1.318 0.269
P – pleural fluid concentration. S – serum concentration. R - 
pleural fluid/serum ratio. P < 0.05 was considered statistically 
significant. Wilks' lambda test is used to test which variables 
significantly contribute in discriminant function analysis. 
F-value is associated with the respective partial Wilks' lambda. 
P-value is associated with the respective F-value.
Table 4. Discriminant function analysis parameters for discrimi-
nation between malignant and non-malignant pleural effu-
sions
Table 5. Logistic regression parameters for prediction of malignant or non-malignant pleural effusions by individual markers and 
their combination 
significant model. However, individual marker’s 
analysis shows that one pleural fluid tumour mark-
er (i.e. NSE) and two serum markers (i.e. NSE and 
CYFRA 21-1) discriminated well between groups 
with malignant and non-malignant pleural effu-
sions. In order to establish the predictive value of 
those markers for classification with respect to 
malignancy of pleural effusion, logistic regression 
analysis was performed. The results presented in 
Table 5 confirm (S) CYFRA 21-1, (S) NSE and (P) NSE 
as good predictors of pleural fluid malignancy and 
establish the model of their combination as highly 
significant (P < 0.001). Additionally, respective ROC 
analysis shows good and significant discrimination 
value of (S) CYFRA 21-1, (S) NSE and (P) NSE combi-
nation.
Table 6 represents an aggregate contingency ta-
ble for these three markers in relation to the diag-
nosis of malignancy. Using this table it is possible 
to determine the specificity and sensitivity of 
these tumour markers (Table 3), using MedCalc 
software.
Discussion
Determining the diagnostic utility of tumour mark-
ers in pleural effusions, especially CEA, NSE, CA-
125, and CYFRA 21-1, has many advantages with 
regard to both cost and the non-invasive ap-
proach, which is why we dedicated the entirety of 
this study to the analysis of these four markers. 
Targeted analysis of tumour markers in pleural ef-
fusions is acceptable, as the price of the test is not 
Biochem Med (Zagreb) 2018;28(1):010706  https://doi.org/10.11613/BM.2018.010706 
8
Volarić D. et al. Tumour markers in pleural effusions
high. A cytomorphological finding of malignant 
cells in pleural effusions and immunocytochemi-
cal analysis can be used as alternative tests for 
greater diagnostic accuracy. Although these tu-
mour markers exhibit great specificity, the low 
sensitivity of each individual marker limits their di-
agnostic value, and a few studies suggested they 
be used along with other pleural effusion tests for 
greater diagnostic accuracy (15). In the present 
study, serum markers were superior to pleural flu-
id markers in determining pleural fluid aetiology. 
Serum CYFRA 21-1, (S) NSE and (P) NSE were shown 
to be most significant predictors of pleural effu-
sion malignancy and their combination produced 
a significant model for distinguishing malignant 
from non-malignant pleural effusions.
The value of a tumour marker lies in its ability to 
exclude or confirm the diagnosis of malignancy. In 
the first case, the marker with greatest sensitivity, 
NPV, and LR- should be used; in the second case 
(to confirm the diagnosis), tumour markers with 
the highest specificity, PPV, and LR+ should be 
used. One marker can be great for confirming di-
agnosis but not so good or very bad at excluding 
the disease and vice versa. In this attempt to ana-
lyse the diagnostic accuracy of these four tumour 
markers, we focused on determining the largest 
AUC, which combines optimum sensitivity and 
specificity in the differentiation of malignant and 
non-malignant pleural effusions. As the pairwise 
comparison of ROC curves yielded a large number 
of results, discriminant function analysis along 
with logistic regression analysis were performed.
Studies of the diagnostic value of tumour markers 
in pleural effusions are not rare, but they have not 
had definitive and clear results (16-21). One study of 
a Polish population concluded that CEA is the bio-
marker with the highest diagnostic utility in malig-
nant pleural effusions, whereas CYFRA 21-1 has 
greater diagnostic value in serum than pleural fluid, 
and NSE has great sensitivity but low diagnostic val-
ue. It was concluded that pleural fluid markers were 
superior to serum markers in determining pleural 
fluid aetiology and that the combination of tumour 
markers may help improve their diagnostic accura-
cy (16). Our study confirmed that serum CYFRA 21-1 
discriminates well between groups with malignant 
and non-malignant pleural effusions but on the 
other hand, CEA marker did not have the highest di-
agnostic utility and NSE was one of the best dis-
criminators considering both serum and pleural val-
ues. Serum markers were found to be superior to 
pleural fluid markers in determining pleural fluid 
aetiology and the combination of (S) CYFRA 21-1, (S) 
NSE and (P) NSE produced a significant model for 
classification of malignant cases. Additionally, re-
Tumour marker
Pleural effusions
Malignant, N Non-malignant, N Total, N
(S) CYFRA 21-1 
Positive (> 3.5 µg/mL) 42 14 56
Negative (≤ 3.5 µg/mL) 13 31 44
Total 55 45 100
(S) NSE
Positive (> 13.3 ng/mL) 45 19 64
Negative (≤ 13.3 ng/mL) 10 26 36
Total 55 45 100
(P) NSE 
Positive (> 4.9 ng/mL) 45 19 64
Negative (≤ 4.9 ng/mL) 10 26 36
Total 55 45 100
Table 6. Serum tumour markers in relation to malignant and non-malignant effusions – contingency tables
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spective ROC analysis showed good and significant 
discrimination value of their combination (AUC = 
0.79). In contrast, a study conducted in the Iranian 
population reported that the highest specificity 
was obtained with a combination of serum and 
pleural fluid CA 15-3 and NSE (100%), and a combi-
nation of serum and pleural fluid CA 15-3, NSE, and 
CEA (100%), whereas the highest sensitivity was ob-
tained with a combination of serum and pleural flu-
id CA 15-3 and CEA (80%), as well as a combination 
of serum and pleural fluid CA 15-3, NSE, and CEA 
(80%) (17). 
The median pleural fluid concentrations for the in-
vestigated tumour markers were higher in malig-
nant effusions than benign effusions, with the ex-
clusion of CA-125. This can be explained by the 
fact that pleural effusions are a filtrate of blood 
plasma and, therefore, the values of tumour mark-
ers do not significantly differ between pleural ef-
fusions and serum. Mechanisms involved in the 
production of pleural effusions are numerous, the 
most common of which are increased hydrostatic 
pressure in lung capillaries, reduction of colloid-
osmotic blood pressure, increased capillary per-
meability in the lungs, decreased pressure in the 
pleural space, lymphatic vessel obstruction in the 
thorax, and increased pressures in the systemic 
vein bloodstream. The values of individual tumour 
markers depend on the dominating mechanism 
involved in the development of the pleural effu-
sion. Pleural fluid CA-125 concentrations deviate 
from the other three markers tested in this study 
because CA-125 is also elevated in the serum of 
patients suffering from non-malignant diseases 
(e.g., endometriosis, tuberculosis, purulent pleuri-
sy and peritonitis, hepatitis, liver cirrhosis) (18). An 
examination of serum marker values showed that 
CYFRA 21-1 and NSE concentrations were higher in 
the group of patients diagnosed with malignant 
effusions, whereas there was no difference in CA-
125 and CEA concentrations between the groups. 
This finding may be due to the fact that CYFRA 
21-1 and NSE are more specific markers than CEA 
and CA-125. The pleural fluid/serum ratios of CEA 
and NSE were also higher in malignant effusions, 
whereas those of CA-125 and CYFRA 21-1 exhibit-
ed no differences. 
The pleural fluid/serum ratio for CEA had one of 
the highest AUC values (i.e. 0.80) (19). The Polish 
study included the CEA marker ratio and reported 
an AUC of 0.84 (16). CEA concentrations in pleural 
fluid had the third highest AUC of 0.75. Pleural flu-
id CEA concentrations were reported in previous 
studies to have an AUC of 0.83, 0.72, and 0.86 
(16,20,21). The dissimilarities between the results 
may be due to different primary diagnoses of the 
patients in the studies. When referring to serum 
CEA concentrations in our study, the AUC was 0.61. 
This marker has great specificity but lacks sensitiv-
ity, and when analysing the serum CEA AUC values 
in accordance with other examined markers, we 
found that the serum CEA concentrations do not 
have great diagnostic value.
Another valuable diagnostic marker according to 
the present study is CYFRA 21-1, but primarily con-
sidering the serum values. The AUC for serum CY-
FRA 21-1 was 0.79 and was proven by discriminant 
function analysis to be one of the best discrimina-
tors regarding pleural fluid aetiology. Logistic re-
gression analysis also discovered serum CYFRA 
21-1 to be one of the three best predictors of pleu-
ral effusion malignancy, according to this study. In 
a previous study by Korczynski et al. the AUC for 
serum CYFRA 21-1 was 0.78, whereas Li et al. differ-
entiated malignant from benign effusions with a 
sensitivity of 56%, specificity of 87%, and diagnos-
tic accuracy of 0.71 (16,22). Although serum CYFRA 
21-1 concentrations are used primarily for the de-
tection of epidermoid lung carcinoma, some stud-
ies have proposed this marker as a method of 
stratifying risk in mesothelioma, oral squamous 
cell carcinoma, and colorectal cancer (23-26). In 
our study, the pleural fluid concentrations of this 
marker had an AUC of 0.72, similar to NSE in serum 
and pleural fluid. A slightly lower AUC of 0.69 for 
serum CYFRA 21-1 was reported in the Polish study 
(16). The pleural fluid/serum ratio for CYFRA 21-1 
was one of the worst diagnostic predictors, with 
an AUC of 0.54. 
NSE is currently the most reliable tumour marker 
in the diagnosis, prognosis, and follow-up of small 
cell lung cancer (SCLC), even though increased 
NSE concentrations have been reported in non-
small cell lung cancer (NSCLC) (27). We found an al-
Biochem Med (Zagreb) 2018;28(1):010706  https://doi.org/10.11613/BM.2018.010706 
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most identical AUC value for NSE in serum and 
pleural fluid. The AUC for the serum measure-
ments was 0.73, whereas the pleural measure-
ments had an AUC of 0.70. The AUC for the NSE ra-
tio was 0.62. Discriminant function analysis 
showed serum and pleural NSE values to be one of 
the best discriminators regarding pleural fluid ae-
tiology and also logistic regression analysis proved 
these two markers to be two of the three best pre-
dictors with respect to malignancy of pleural effu-
sion. According to this study, serum and pleural 
fluid NSE concentrations were found to be a more 
useful diagnostic tool than in results reported by 
Korczynski et al. and Lee et al. (16,21).
Although CA-125 was discovered 30 years ago, the 
Food and Drug Administration (FDA) still recom-
mends it to monitor the response to therapy in pa-
tients with epithelial ovarian cancer and to detect 
residual or recurrent disease in patients who have 
undergone first-line therapy and who would be 
considered for second-look procedures (28). The 
present study showed that CA-125 has the lowest 
diagnostic utility of all markers studied. The AUC 
for this marker in the serum was 0.50, nearly the 
same value as the marker in pleural fluid (AUC = 
0.55) and the pleural fluid/serum ratio (AUC = 0.51). 
In contrast, the AUC values for CA-125 in the Polish 
study were 0.60, 0.64, and 0.54 for serum, pleural 
fluid, and the ratio, respectively.
The present study has some limitations. Although 
the patients were included as a consecutive series, 
the fact that the study was performed in the De-
partment of Pulmonology has the consequence of 
exposure to more diseases related to lung pathol-
ogy. In addition, the number of patients included 
in this study is representative of the size of the 
medical facility where the study was performed. 
Furthermore, the present study does not evaluate 
a larger number of different tumour markers (e.g., 
CA 15-3, CA 19-9, PSA, etc.) or compare their diag-
nostic utility with more classical laboratory tests 
(e.g. LD, albumin etc.).
The advantage of this study is that it is a real-time 
study conducted in a Croatian population; differ-
ences exist in the expression of particular tumour 
markers in different races and populations due to 
genetic susceptibility.
In conclusion, we have shown that certain tumour 
markers have a higher diagnostic value than oth-
ers in Croatian patients. Serum markers were supe-
rior to pleural fluid markers in determining pleural 
fluid aetiology, according to this study. Serum CY-
FRA 21-1 concentrations, serum and pleural NSE 
values were found to be most significant predic-
tors of pleural effusion malignancy and the combi-
nation of these three entities produced a signifi-
cant model for distinguishing malignant from 
non-malignant pleural effusions. Further research 
in other populations and larger study groups is 
needed to determine whether measuring tumour 
markers in pleural effusions is appropriate in gen-
eral.
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